All In Biotech

Drug Trial Radar · NCT06172309

A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors

A Phase I Study of Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic Effect of NTQ1062 Tablets in Chinese Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Sep 24, 2021

Primary completion

Apr 20, 2024

Study completion May 27, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effect of NTQ1062 in patients with advanced solid tumors. The study comprises a dose-escalation phase and a dose-expansion phase. 1. Dose-escalation:using 3+3 design to evaluate the safety, tolerability, and pharmacokinetic profile of NTQ1062 at 20, 50, 100, 200, 300, 400 mg in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD). 2. Dose-expansion:the dose-expansion study will evaluate the safety, tolerability, and preliminary pharmacodynamic effect of the MTD for NTQ1062 in patients with advanced solid tumors, and to identify the recommended phase 2 dose (RP2D).

Conditions

  • Advanced Solid Tumors

Interventions

  • NTQ1062Drug

    tablet(s) PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: First treatment cycle (i.e., the first 28 days post the first dose)
  2. Recommended phase 2 dose (RP2D)Time frame: First treatment cycle (i.e., the first 28 days post the first dose)
  3. Adverse eventsTime frame: through study completion, an average of 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shanghai East hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.